Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The PRDM4 mRNA 3'-untranslated region (3'-UTR) is a critical regulatory segment of the messenger RNA encoding the PR domain zinc finger protein 4 (PRDM4), also known as SC1 or PFM1 (UniProt Q9UKN5). This region contains specific sequences that serve as binding sites for microRNAs (miRNAs) and RNA-binding proteins, which govern the stability and translation efficiency of the PRDM4 transcript (PLoS One 2013, 8(8):e72149). PRDM4 itself functions as a transcription factor and epigenetic modifier, playing vital roles in neural stem cell maintenance, cell cycle regulation, and tumor suppression by interacting with partners like PRMT5 and HDACs (J Biol Chem 2012, 287(51):42995-43006). Dysregulation of the PRDM4 3'-UTR, such as through the binding of oncogenic miRNAs like miR-373 or the loss of tumor-suppressive miRNAs like miR-16, can lead to aberrant PRDM4 protein levels (Oncogene 2021, 40(18):3318-3330). This dysregulation is linked to the progression of various cancers, including cervical and gastric malignancies, where PRDM4 often acts as a tumor suppressor (Oncogene 2021, 40(18):3318-3330). While no small molecule drugs currently target this specific RNA region, it represents a promising site for the development of RNA-based therapeutics, such as antisense oligonucleotides or miRNA mimics, designed to precisely modulate PRDM4 expression. Targeting the 3'-UTR offers a mechanism to restore protein levels in contexts where PRDM4 is silenced, providing a novel avenue for cancer and neurodevelopmental therapies.
Post-transcriptional regulation of PRDM4 protein levels through microRNA-mediated mRNA degradation or translational inhibition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PR domain zinc finger protein 4 messenger RNA 3'-untranslated region (PRDM4 mRNA 3'-UTR).